Back grey_arrow_rt.gif
 
 
Merck Appoints Dr. Michael Rosenblatt
As Executive Vice President & Chief Medical Officer
 
 
 
 
WHITEHOUSE STATION, N.J. - December 16, 2009 - Merck & Co., Inc. (NYSE: MRK) today announced the appointment of Dr. Michael Rosenblatt as Executive Vice President and Chief Medical Officer, effective immediately. Dr. Rosenblatt will be Merck's primary voice to the global medical community and will speak to critical issues such as patient safety.
 
He will have responsibility for bringing even greater focus to Merck's medical activities worldwide as well as shaping innovative medical strategies that meet the needs of our customers in new and better ways. Dr. Rosenblatt will report directly to Richard T. Clark, Merck's chairman, president and chief executive officer, will serve on the company's Executive Committee and will oversee the company's Global Center for Scientific Affairs.
 
"Merck's fundamental mission is ensuring the well-being of patients worldwide and Dr. Rosenblatt's appointment reinforces our steadfast commitment to always remain focused on this goal," said Mr. Clark. "Dr. Rosenblatt's achievements in academia, clinical medicine and private industry are exceptional. With his nearly three decades of invaluable experience, I am pleased to welcome Dr. Rosenblatt to Merck's executive team."
 
Dr. Rosenblatt said, "Merck has built a great foundation on scientific innovation and dedication to the well-being of patients around the world and put an amazing team of researchers and scientists in place to drive the next wave of innovative products and services that save and improve lives. I look forward to working with my colleagues to make a difference in the lives of people around the world. Merck is a global health care leader with a broad, diversified portfolio of innovative medicines and vaccines and I couldn't be more pleased to join this fine organization."
 
Dr. Rosenblatt has served as Dean of Tufts University School of Medicine since 2003. Prior to Tufts University, Dr. Rosenblatt held the appointment of George R. Minot Professor of Medicine at Harvard Medical School and Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center (BIDMC). He served as the President of BIDMC from 1999-2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for Academic Programs at CareGroup and BIDMC and a founder of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and BIDMC. Prior to that, he served as Director of the Harvard-MIT Division of Health Sciences and Technology. And earlier, he was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he co-led the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders. In leading most of Merck's international research efforts, he established two major basic research institutes. He also headed Merck Research's worldwide University and Industry Relations Department. Dr. Rosenblatt is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman's Award from Merck. Dr. Rosenblatt received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org